References
- Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 2000;89: 630–9
- Carbone D. Smoking and cancer. Am J Med 1992;93: 13S–17S
- Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996;274: 430–2
- Vineis P, Caporaso N. Tobacco and cancer: epidemiology and the laboratory. Environ Health Perspect 1995;103: 156–60
- Westra WH, Slebos RJ, Offerhaus GJ, et al. K-ras oncogene activation in lung adenocarcinomas from former smokers: evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 1993;72: 432–8
- Westra WH, Offerhaus GJ, Goodman SN, et al. Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol 1993;17: 213–20
- Westra WH, Baas IO, Hruban RH, et al. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res 1996;56: 2224–8
- Sauter G, Algaba F, Amin AB, et al. Noninvasive urothelial tumors. In: Elbe JN, Sauter G, Epstein JI, Sesterhenn IA, eds. Pathology and Genetics: Tumors of the Urinary System and Male Genital Organs. Lyon: IARC Press;2004: 110–11
- Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000;163: 73–8
- Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001;19: 666–75
- Stellman SD, Resnicow K. Tobacco smoking, cancer and social class. IARC Sci Publ 1997;138: 229–50
- Meliska CJ, Stunkard ME, Gilbert DG, et al. Immune function in cigarette smokers who quit smoking for 31 days. J Allergy Clin Immunol 1995;95: 901–10
- Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, et al. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res 2001;61: 1309–13
- Martinez-Pineiro JA, Flores N, Isorna S, et al., for CUETO (Club Urologico Espanol de Tratamiento Oncologico). Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacilli Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 2002;89: 671–80
- Fleshner N, Garland J, Moadel A, et al. Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder. Cancer 1999;86: 2337–45
- Serretta V, Altieri V, Morgia G, et al. Cigarette smoking and drinking water source: correlation with clinical features and pathology of superficial bladder carcinoma. Urol Int 2009;82: 318–23
- Chen CH, Shun CT, Huang KH, et al. Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer. BJU Int 2007;100: 281–6
- Jiang X, Yuan JM, Skipper PL, et al. Environmental tobacco smoke and bladder cancer risk in never smokers of Los Angeles County. Cancer Res 2007;67: 7540–5
- Garcia Mediero JM, Angulo CJ, Lujan GM, et al. Smoking habit and superficial bladder tumours’ natural history [in Spanish]. Actas Urol Esp 2007;31: 349–54
- Lee C, Kim KH, You D, In: Jeong G, Hong B, Hong JH, Ahn H, Kim CS. Smoking and survival after radical cystectomy for bladder cancer. Urology 2012;80: 1307–12